The Expression of HBME1, PAX8, CD56 and CITED1 in Benign Lesions, Benign and Malignant Tumors of Thyroid

KULAÇOĞLU, SEZER; Erkilinc, Gamze

doi:10.5505/aot.2021.26818

The Expression of HBME1, PAX8, CD56 and CITED1 in Benign Lesions, Benign and Malignant Tumors of Thyroid

Gamze ERKILINÇ, (Süleyman Demirel Üniversitesi, Patoloji Anabilim Dalı, Isparta, Türkiye)

Sezer KULAÇOĞLU (Ankara Şehir Hastanesi, Patoloji Anabilim Dalı, Ankara, Türkiye)

ACTA ONCOLOGICA TURCICA

2 0

Yıl: 2021 Cilt: 54 Sayı: 2 Sayfa Aralığı: 141 - 151 Metin Dili: İngilizce DOI: 10.5505/aot.2021.26818 İndeks Tarihi: 20-12-2021

The Expression of HBME1, PAX8, CD56 and CITED1 in Benign Lesions, Benign and Malignant Tumors of Thyroid

Öz:

Introduction: To evaluate the role of HBME1, PAX8, CD56 and CITED1 in distunguishing benign lesions of the thyroid from malignant tumors and different malignant tumors of the thyroid. Methods: The patients that underwent thyroidectomy between 2007 and 2013 were included to the study. Patients with Nodular Hyperplasia: 22, Folicular Adenoma: 14, Noninvasive Folicular Thyroid Neoplasm With Papillary-Like Nuclear Features: 3, Well Diferentiated Carcinoma, Not Otherwise Specified: 3, Papillary Carcinoma: 22, Papillary Carcinoma Folicular Variant: 12, Minimally Invasive Folicular Carcinoma: 9, Poorly Diferentiated Carcinoma: 4, Anaplastic Carcinoma: 3 were included to the study. HBME1, CITED1, PAX8, CD56 were applied by immunohistochemical method. In statistical analysis, the sensitivity, specificity, positive predictive and negative predictive values of markers were calculated. Results: CD56 (loss of expression), HBME1 was significantly higher in Papillary Carcinoma, Papillary Carcinoma Folicular Variant compared to other malignant neoplasms. The most sensitive markers for malignant tumors were PAX8 and CITED1 (90%, 88%). The most specific markers for malignant tumors were HBME1, CITED1 (97%, 92%). The most sensitive and specific marker for Papillary Carcinoma, Papillary Carcinoma Folicular Variant was HBME1 (100%, 80%). CD56 (loss of expression), CITED1 was the most sensitive markers for Papillary Carcinoma Folicular Variant (86%, 86%). Discussion and conclusion: HBME1 was found an both sensititive and specific marker for Papillary Carcinoma. The cytoplasmic expression of CITED1 was significantly higher in PC compared to other malignant tumors. Nuclear expression of PAX8 was found significantly higher in benign cases compared to malignant tumors. HBME1, CD56 (loss of expression) was found significantly higher in Papillary Carcinoma, Papillary Carcinoma Folicular Variant compared to other malignant tumors.

Anahtar Kelime:

Tiroidin Benign Lezyonları, Benign ve Malign Tümörlerinde HBME1, PAX8, CD56 ve CITED1 Ekspresyonun Değerlendirilmesi

Öz:

Giriş ve amaç: HBME1, PAX8, CD56 ve CITED1’ in tiroidin benign lezyonlarını, malign tümörlerden ve tiroidin farklı malign tümörlerini birbirinden ayırt etmedeki rolünü değerlendirmektir. Yöntem ve gereçler: 2007-2013 yılları arasında tiroidektomi yapılan Nodüler Hiperplazi: 22, Foliküler Adenoma: 14, Papiller Benzeri Nükleer Özellikler Gösteren non-İnvaziv Foliküler Tiroid Neoplazmı: 3, İyi Diferansiye Karsinoma, Spesifiye Edilememiş: 3, Papiller Karsinoma: 22, Papiller Karsinoma, Foliküler Varyant: 12, Minimal İnvaziv Foliküler Karsinoma: 9, Az Diferansiye Karsinoma: 4, Anaplastik Karsinoma: 3 çalışmaya dahil edildi. İmmünhistokimyasal yöntem ile HBME1, CITED1, PAX8, CD56 uygulandı. İstatistiksel analizde markerlerın duyarlılık, özgüllük, pozitif ve negatif prediktif değerleri hesaplandı. Bulgular: CD56 (ekspresyon kaybı), HBME1, Papiller Karsinoma ve Papiller Karsinoma, Foliküler Varyantta, diğer malign tümörlere göre anlamlı yüksekti. Malign tümörler için en duyarlı markerlar PAX8 ve CITED1 (%90, %88) idi. Malign tümörler için en spesifik markerlar HBME1, CITED1 (%97, %92)idi. Papiller Karsinoma, Papiller Karsinoma, Foliküler Varyant için en duyarlı ve spesifik marker HBME1 (%100, %80) idi. Papiller Karsinoma, Folliküler Varyant için en duyarlı markerlar CD56 (ekspresyon kaybı) ve CITED1 (%86, %86)idi. Tartışma ve sonuç: HBME1, Papiller Karsinoma için duyarlı ve spesifik bulundu. CITED1’in sitoplazmik ekspresyonun Papiller Karsinomada, tiroidin diğer malign tümörlerine göre anlamlı şekilde yüksekti. PAX8'in nükleer ekspresyonu benign olgularda malign olgulara göre anlamlı şekilde yüksek bulundu. HBME1, CD56 (ekspresyon kaybı), Papiller Karsinoma ve Papiller Karsinoma, Foliküler Varyantta diğer malign tümörlere göre anlamlı şekilde yüksek bulundu.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Basu S, Nair N, Borges AM. Aggressive behaviour of solid arrangement pattern in differentiated papillary carcinoma of thyroid. Journal- Association of Physicians of India. 2003; 51: 408-11.
2. Rossi E, Raffaelli M, Mule' A, Miraglia A, Lombardi CP, Vecchio FM, et al. Simultaneous immunohistochemical expression of HBME‐1 and galectin‐3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology. 2006; 48(7): 795-800.
3. Prasad ML, Pellegata NS, Kloos RT, Barbacioru C, Huang Y, de la Chapelle AJT. CITED1 protein expression suggests papillary thyroid carcinoma in high throughput tissue microarray-based study. Thyroid. 2004; 14(3): 169-75.
4. El Demellawy D, Nasr AL, Babay S, Alowami S. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid. Pathology- Research and Practice. 2009; 205(5): 303-9.
5. Kroll TG, Sarraf P, Pecciarini L, Chen C-J, Mueller E, Spiegelman BM, et al. PAX8-PPARγ1 fusion in oncogene human thyroid carcinoma. Science. 2000; 289(5483) :1357-60.
6. Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos A, et al. Characterization of thyroid ‘follicular neoplasms’ in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocrine-related cancer. 2005; 12(2): 305-17.
7. Carpi A, Mechanick JI, Saussez S, Nicolini A. Thyroid tumor marker genomics and proteomics: diagnostic and clinical implications. Journal of cellular physiology. 2010; 224(3): 612-9.
8. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. New England Journal of Medicine. 2012; 367(8): 705-15.
9. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SLJMp. Immunohistochemical diagnosis of papillary thyroid carcinoma.Modern Pathology. 2001; 14(4): 338-42.
10. Atik E, Guray M, Gunesacar R, Ozgur T, Canda T. Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation. Indian journal of cancer. 2014;51(1):63.
11. Scognamiglio T, Hyjek E, Kao J, Chen Y-T. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. American Journal of Clinical Pathology. 2006; 126(5):700-8.
12. Liu YY, Morreau H, Kievit J, Romijn JA, Carrasco N, Smit JWJEJoE. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-γ, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. European Journal of Endocrinology. 2008; 158(3):375-84.
13. Fischer S, Asa SL. Application of immunohistochemistry to thyroid neoplasms. Archives of pathology & laboratory medicine. 2008;132(3):359- 72.
14. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT. Galectin-3, fibronectin- 1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Modern Pathology. 2005; 18(1): 48.
15. Marques AR, Espadinha C, Catarino AL, Moniz Sn, Pereira T, Sobrinho LsG, et al. Expression of PAX8- PPARγ1 rearrangements in both follicular thyroid carcinomas and adenomas. The Journal of Clinical Endocrinology & Metabolism. 2002; 87(8): 3947-52.
16. Eberhardt NL, Grebe SK, McIver B, Reddi HV. The role of the PAX8/PPARγ fusion oncogene in the pathogenesis of follicular thyroid cancer. Molecular and cellular endocrinology. 2010; 321(1): 50-6.
17. McIver B, Grebe SK, Eberhardt NL. The PAX8/PPARγ fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. Current Drug Targets-Immune, Endocrine & Metabolic Disorders. 2004; 4(3): 221-34.
18. Lacroix L, Mian C, Barrier T, Talbot M, Caillou B, Schlumberger M, et al. PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues. European Journal of Endocrinology. 2004; 151(3): 367-74.
19. Lenggenhager D, Maggio EM, Moch H, Rössle MJH. HBME‐1 expression in hyalinizing trabecular tumours of the thyroid gland. Histopathology. 2013; 62(7): 1092-7.
20. Nechifor-Boila A, Borda A, Sassolas G, Hafdi- Nejjari Z, Borson-Chazot F, Lifante JC, et al. Immunohistochemical markers in the diagnosis of papillary thyroid carcinomas: The promising role of combined immunostaining using HBME-1 and CD56. Pathology-Research and Practice. 2013;209(9):585-92.
21. Ozolins A, Narbuts Z, Strumfa I, Volanska G, Stepanovs K, Gardovskis J. Immunohistochemical expression of HBME-1, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules. Medicina. 2012; 48(10):74.
22. Abd El Atti RM, Shash LS. Potential diagnostic utility of CD56 and claudin-1 in papillary thyroid carcinoma and solitary follicular thyroid nodules. Journal of the Egyptian National Cancer Institute. 2012; 24(4):175-84.
23. Nechifor-Boila A, Catana R, Loghin A, Radu TG, Borda A. Diagnostic value of HBME-1, CD56, Galectin- 3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential. Romanian Journal of Morphology & Embryology. 2014; 55(1):49-56.
24. Nakamura N, Erickson LA, Jin L, Kajita S, Zhang H, Qian X, et al. Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma. Endocrine Pathology. 2006; 17(3): 213-23.
25. Trimboli P, Guidobaldi L, Amendola S, Nasrollah N, Romanelli F, Attanasio D, et al. Galectin-3 and HBME-1 improve the accuracy of core biopsy in indeterminate thyroid nodules. Endocrine. 2016; 52(1): 39-45.

APA	Erkilinc G, KULAÇOĞLU S (2021). The Expression of HBME1, PAX8, CD56 and CITED1 in Benign Lesions, Benign and Malignant Tumors of Thyroid. , 141 - 151. 10.5505/aot.2021.26818
Chicago	Erkilinc Gamze,KULAÇOĞLU SEZER The Expression of HBME1, PAX8, CD56 and CITED1 in Benign Lesions, Benign and Malignant Tumors of Thyroid. (2021): 141 - 151. 10.5505/aot.2021.26818
MLA	Erkilinc Gamze,KULAÇOĞLU SEZER The Expression of HBME1, PAX8, CD56 and CITED1 in Benign Lesions, Benign and Malignant Tumors of Thyroid. , 2021, ss.141 - 151. 10.5505/aot.2021.26818
AMA	Erkilinc G,KULAÇOĞLU S The Expression of HBME1, PAX8, CD56 and CITED1 in Benign Lesions, Benign and Malignant Tumors of Thyroid. . 2021; 141 - 151. 10.5505/aot.2021.26818
Vancouver	Erkilinc G,KULAÇOĞLU S The Expression of HBME1, PAX8, CD56 and CITED1 in Benign Lesions, Benign and Malignant Tumors of Thyroid. . 2021; 141 - 151. 10.5505/aot.2021.26818
IEEE	Erkilinc G,KULAÇOĞLU S "The Expression of HBME1, PAX8, CD56 and CITED1 in Benign Lesions, Benign and Malignant Tumors of Thyroid." , ss.141 - 151, 2021. 10.5505/aot.2021.26818
ISNAD	Erkilinc, Gamze - KULAÇOĞLU, SEZER. "The Expression of HBME1, PAX8, CD56 and CITED1 in Benign Lesions, Benign and Malignant Tumors of Thyroid". (2021), 141-151. https://doi.org/10.5505/aot.2021.26818

APA	Erkilinc G, KULAÇOĞLU S (2021). The Expression of HBME1, PAX8, CD56 and CITED1 in Benign Lesions, Benign and Malignant Tumors of Thyroid. ACTA ONCOLOGICA TURCICA, 54(2), 141 - 151. 10.5505/aot.2021.26818
Chicago	Erkilinc Gamze,KULAÇOĞLU SEZER The Expression of HBME1, PAX8, CD56 and CITED1 in Benign Lesions, Benign and Malignant Tumors of Thyroid. ACTA ONCOLOGICA TURCICA 54, no.2 (2021): 141 - 151. 10.5505/aot.2021.26818
MLA	Erkilinc Gamze,KULAÇOĞLU SEZER The Expression of HBME1, PAX8, CD56 and CITED1 in Benign Lesions, Benign and Malignant Tumors of Thyroid. ACTA ONCOLOGICA TURCICA, vol.54, no.2, 2021, ss.141 - 151. 10.5505/aot.2021.26818
AMA	Erkilinc G,KULAÇOĞLU S The Expression of HBME1, PAX8, CD56 and CITED1 in Benign Lesions, Benign and Malignant Tumors of Thyroid. ACTA ONCOLOGICA TURCICA. 2021; 54(2): 141 - 151. 10.5505/aot.2021.26818
Vancouver	Erkilinc G,KULAÇOĞLU S The Expression of HBME1, PAX8, CD56 and CITED1 in Benign Lesions, Benign and Malignant Tumors of Thyroid. ACTA ONCOLOGICA TURCICA. 2021; 54(2): 141 - 151. 10.5505/aot.2021.26818
IEEE	Erkilinc G,KULAÇOĞLU S "The Expression of HBME1, PAX8, CD56 and CITED1 in Benign Lesions, Benign and Malignant Tumors of Thyroid." ACTA ONCOLOGICA TURCICA, 54, ss.141 - 151, 2021. 10.5505/aot.2021.26818
ISNAD	Erkilinc, Gamze - KULAÇOĞLU, SEZER. "The Expression of HBME1, PAX8, CD56 and CITED1 in Benign Lesions, Benign and Malignant Tumors of Thyroid". ACTA ONCOLOGICA TURCICA 54/2 (2021), 141-151. https://doi.org/10.5505/aot.2021.26818